Service Quote Request
Please fill out the form below with your detailed inquiry.
Summary Table: Gastrointestinal-Specific AAV Promoters
| Tissue/Cell Type | Promoter | AAV-Optimized Size | Target | Note on Longevity |
| Intestinal Epithelium | Villin | ~1.5 – 2.5 kb | All mature enterocytes | High turnover; expression is transient unless stem cells are hit. |
| Enterocytes | Fabp1 | ~1.0 – 1.5 kb | Small Intestine/Liver | Often includes a 3′ enhancer for potency. |
| Goblet Cells | MUC2 | ~1.5 – 2.0 kb | Mucus-secreting cells | Truncated versions used to target the colonic/intestinal barrier. |
| Stem Cells | Lgr5 | ~2.0 kb | Crypt Base Stem Cells | High value: Targeting these allows for permanent lineage tracing. |
| Stomach G-Cells | Gastrin | ~0.5 – 1.3 kb | Gastric Antrum | Smaller fragments are highly effective for endocrine targeting. |
Key Technical Considerations for GI AAVs
1. The “Turnover” Problem
Because enterocytes and goblet cells are shed so frequently, an AAV targeting mature cells (using Villin or Fabp1) will only show expression for about a week. To achieve long-term expression, you must target the Lgr5+ stem cells located at the base of the crypts.
2. Local vs. Systemic Delivery
- Systemic (IV): AAV9 and AAV-PHP.S can reach the enteric nervous system and some epithelial layers, but much of the dose is sequestered by the liver.
- Local (Intraluminal): Delivering the AAV directly into the intestinal lumen (via endoscopy or surgery) is often preferred to increase local concentration, though the mucus barrier (targeted by MUC2) can act as a physical shield.
3. Enhancing Specificity
If using Fabp1, be aware that it is also naturally expressed in the liver. To ensure your construct is truly GI-specific:
- Use a truncated Villin promoter (often 1.5 kb), which has much tighter intestinal specificity compared to Fabp1.
- Include miR-122 target sites to suppress any viral particles that accidentally transduce hepatocytes.
Important updates waiting for you!
Enter your email address below and subscribe to our newsletter